Xenotransplantation

Current Opinion in Nephrology and Hypertension

Volumn 5, Issue 6, 1996, Pages 514-518

  Cozzi, Emanuele ^a,b   White, David J G ^a,c  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF PADOVA   (Italy)

^c Douglas House ^*  (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT ACTIVATION; GRAFT REJECTION; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; NONHUMAN; PRIORITY JOURNAL; REVIEW; SWINE; TRANSGENIC ANIMAL; TRANSPLANTATION; XENOGRAFT;

ACUTE DISEASE; ANIMALS; COMPLEMENT ACTIVATION; ENDOTHELIUM, VASCULAR; GRAFT REJECTION; HUMANS; IMMUNITY, CELLULAR; ORGAN TRANSPLANTATION; SWINE; TRANSPLANTATION IMMUNOLOGY; TRANSPLANTATION, HETEROLOGOUS;

EID: 0030464388     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041552-199611000-00010     Document Type: Review

References (48)

1. Cooper DKC, Ye Y, Rolf JLL, Zuhdi N: The pig as potential organ donor for man. In Xeno-transplantation: the transplantation of organs and tissues between species, 1st edn. Edited by Cooper DKC, Kemp E, Reemtsma K, White DJG. Berlin: Springer-Verlag; 1991:481-500.
2. Allan JS: Xenotransplantation at a crossroads: prevention versus progress. Nat Med 1996, 2:18-21.
3. Platt JL, Bach FH: The barrier to xenotransplantation. Transplantation 1991, 52:937-947.
4. Dalmasso AP, Vercellotti GM, Fischel RJ, Bolman RM, Bach FH, Platt JL: Mechanisms of complement activation in the hyperacute rejection of porcine organs transplanted into primate recipients. Am J Pathol 1992, 140:1157-1166.
5. Sandrin MS, Vaughan HA, Dabkowski PL, McKenzie IFC: Anti-pig IgM antibodies in human serum react predominantly with Gal(α1-3)Gal epitopes. Proc Natl Acad Sci U S A 1993, 90:11391-11395.
6. Galili U: Interaction of the natural anti-Gal antibody with α-galactosyl epitopes: a major obstacle for xenotransplantation in humans. Immunol Today 1993, 14:480-482.
7. Parker W, Bruno D, Holzknecht ZE, Platt JL: Characterization and affinity isolation of xenoreactive human natural antibodies. J Immunol 1994, 153:3791-3803.
8. Holzknecht ZE, Platt JL: Identification of porcine endothelial cell membrane antigens recognised by human xenoreactive natural antibodies. J Immunol 1995, 154:4565-4575. This paper provides a detailed characterization of the antigens recognized by naturally occurring human XNAs and offers a new insight into the pathogenesis of xenograft rejection.
9. Galili U, Gregory CR, Morris RE: Contribution of anti-Gal to primate and human IgG binding to porcine endothelial cells. Transplantation 1995, 60:210-213.
10. Gautreau C, Kojima T, Woimant G, Cardoso J, Deviller P, Houssin D: Use of intravenous immunoglobulin to delay xenogeneic hyperacute rejection: an in vivo and in vitro evaluation. Transplantation 1995, 60:903-907.
11. Magee JC, Collins BH, Harland RC, Lindman BJ, Bollinger RR, Frank MM, Platt JL: Immunoglobulin prevents complement-mediated hyperacute rejection in swine-to-primate xenotransplantation. J Clin Invest 1995, 96:2404-2412. This paper demonstrates that IgG administration prevents hyperacute rejection in the pig-to-primate model and presents evidence that it is through the regulation of complement that rejection is averted.
12. Galili U, Tibell A, Samuelsson B, Rydberg L, Groth CG: Increased anti-Gal activity in diabetic patients transplanted with fetal porcine islet cell clusters. Transplantation 1995, 59:1549-1556.
13. Cotterell AH, Collins BH, Parker W, Harland RC, Platt JL: The humoral immune response in humans following cross-perfusion of porcine organs. Transplantation 1995, 60:861-868.
14. Geller RL, Rubinstein P, Platt JL: Variation in expression of porcine xenogeneic antigens. Transplantation 1994, 58:272-277.
15. Alvarado CG, Cotterell AH, McCurry KR, Collins BH, Magee JC, Berthold J, Logen JS, Platt JL: Variation in the level of xenoantigen expression in porcine organs. Transplantation 1995, 59:1589-1596. This paper demonstrates conclusively the existence of a quantitative relationship between the binding of xenoreactive natural antibodies to platelets and to whole organs. The advantage conferred to a pig graft by the tow expression of xenoantigens is also demonstrated in an ex vivo perfusion model.
16. Cairns T, Lee J, Goldberg L, Cook T, Simpson P, Spackman D, Palmer A, Taube D: Inhibition of the pig to human xenograft reaction, using soluble Galα1-3Gal and Galα1-3Galβ1-4GlcNAc. Transplantation 1995, 60:1202-1207.
17. Rieben R, Von Allmen E, Korchagina EY, Nydeger UE, Neethling FA, Kujundzic M, Koren E, Bovin NV, Cooper DKC: Detection, immunoabsorption, and inhibition of cytotoxic activity of anti-αGal antibodies using newly developed substances with synthetic Galα1-3Gal disaccharide epitopes. Xenotransplantation 1995, 2:98-106.
18. McKenzie IFC, Cohney S, Vaughan HA, Osman N, Atkin J, Elliott E, Fodor WL, Gallop MA, Oldenburg KR, Burton D, Sandrin MS: Overcoming the anti-Galα(1-3)Gal reaction in xenotransplantation. Xenotransplantation 1995, 3:86-88. This paper is a comprehensive review describing the different strategies which have been attempted to overcome the anti-Galα1-3Gal epitope reaction in xenotransplantation.
19. Kooyman DL, McClellan SB, Parker W, Avissar PL, Velardo MA, Platt JL, Logan JS: Identification and characterization of a galactosyl peptide mimetic. Transplantation 1996, 61:851-855.
20. Tearle RG, Tange MJ, Zannettino ZL, Katerelos M, Shinkel TA, Van Denderen BJW, Lonie AJ, Lyons I, Nottle MB, Cox T et al.: The α-1,3-galactosyltransferase knockout mouse: Implications for xenotransplantation. Transplantation 1996, 61:13-19. This paper describes, for the first time, the production of knockout mice for the α-1,3-galactosyltransferase. The data presented demonstrate a substantial reduction in human complement activation on cells from these mice as a consequence of the absence of the expression of Galα1-3Gal epitope.
21. Sandrin MS, Fodor WL, Mouhtouris E, Osman N, Cohney S, Rollins SA, Guilmette ER, Setter E, Squinto SP, McKenzie IFC: Enzymatic remodelling of the carbohydrate surface of a xenogenic cell substantially reduces human antibody binding and complement-mediated cytotolysis. Nature Med 1995, 1:1261-1267. This paper demonstrates that it is possible to reduce the expression of the Galα1-3Gal epitope on the surface of porcine cells by replacing it with the non-antigenic universal donor human blood group O antigen, α-1,2-fucosyl lactosamine moiety. As a result, cells expressing the human α1-3 galactosyltransferase were shown to be resistant to human natural antibody binding and complement-mediated lysis. The first transgenic mice expressing the human H-transferase are also described.
22. Zhao Z, Termignon JL, Cardoso J, Chereau C, Gautreau C, Calmus Y, Houssin D, Weill B: Hyperacute xenograft rejection in the swine-to-human donor-recipient combination: in vitro analysis of complement activation. Transplantation 1994, 57:245-249.
23. Makowka L, Cramer DV, Hoffman A, Breda M, Sher L, Eiras-Hreha G, Tuso PJ, Yasunga C, Cosenza CA, Wu DG et al.: The use of a pig liver xenograft for temporary support of a patient with fulminant hepatic failure. Transplantation 1995, 59:1654-1659.
24. Ryan US: Complement inhibitory therapeutics and xenotransplantation. Nature Med 1995, 1:967-968.
25. Leventhal JR, Dalmasso AP, Cromwell JW, Ratt JL, Manival CJ, Bolman RM, Matas AJ: Prolongation of cardiac xenograft survival by depletion of complement. Transplantation 1993, 55:857-865.
26. Pruitt SK, Kirk DA, Bollinger RR, Marsh HC, Collins BH, Levin JL, Mault JR, Heinle JS, Ibrahim S, Rudolph AR et al.: The effect of soluble complement receptor type 1 on hyperacute rejection of porcine xenografts. Transplantation 1994, 57:363-370.
27. Kroshus TJ, Rollins SA, Dalmasso AP, Elliott EA, Matis LA, Squinto SP, Morton Bolman R: Complement Inhibition with an anti-C5 monoclonal antibody prevents acute cardiac tissue injury In an ex vivo model of pig-to-human xenotransplantation. Transplantation 1995, 60:1194-1202.
28. Rollins SA, Matis LA, Springhorn JP, Setter E, Wolff DW: Monoclonal antibodies directed against human C5 and C8 block complement-mediated damage of xenogeneic cells and organs. Transplantation 1995, 60:1282-1292.
29. Cozzi E, White DJG: The generation of transgenic pigs as potential organ donors for humans. Nature Med 1995, 1:964-966.
30. Rosengard AM, Cary NRB, Langford GA, Tucker AW, Wallwork J, White DJG: Tissue expression of human complement inhibitor, decay-accelerating factor, in transgenic pigs - a potential approach for preventing xenograft rejection. Transplantation 1995, 59:1325-1333.
31. Fodor WL, Williams BL, Matis LA, Madri JA, Rollins SA, Knight JW, Velander W, Squinto SP: Expression of a functional human complement Inhibitor in a transgenic pig as a model for the prevention of xenogeneic hyperacute organ rejection. Proc Natl Acad Sci U S A 1994, 91:11153-11157.
32. Langford GA, Cozzi E, Yannoutsos N, Lancaster R, Elsome K, Chen P, White DJG: Production of pigs transgenic for human regulators of complement activation using YAC technology. Transplant Proc 1996, 28:862-863.
33. McCurry KR, Kooyman DL, Alvarado CG, Cotterell AH, Martin MJ, Logan JS, Platt JL: Human complement regulatory proteins protect swine-to-primate cardiac xenografts from humoral injury. Nature Med 1995, 1:423-427. This paper gives the first in-vivo evidence that, when transplanted into primates, organs from pigs transgenic for human regulators of complement activation are protected from humoral injury.
34. Cozzi E, Langford GA, Wright L, Tucker A, Yannoutsos N, Richards A, Rosengard A, Elsome K, Lancaster R, White DJG: Comparative analysis of human DAF expression in the tissues of transgenic pigs and man. Transplant Proc 1995, 27:319-320.
35. Cozzi E, Langford GA, Wright L, Pino-Chavez G, Levy A, Chatterjee M, Yannoutsos N, Miller N, Lancaster R, White DJG: Longitudinal analysis of the expression of human decay accelerating factor on peripheral blood mononuclear cells and in the plasma of transgenic pigs. Transplant Proc 1996, 28:860-861.
36. White DJG, Langford GA, Cozzi E, Young VJ: Protective effects of human DAF in transgenic pigs. Xenotransplantation 1995, 3:48-51.
37. Kroshus TJ, Bolman RM III, Dalmasso AP, Rollins SA, Guilmette ER, Williams BL, Squinto SP, Fodor WL: Expression of human CD59 in transgenic pig organs enhances organ survival in an ex vivo xenogeneic perfusion model. Transplantation 1996, 61:1513-1521.
38. Cozzi E, Yannoutsos N, Langford GA, Pino-Chavez G, Wallwork J, White DJG: Effect of transgenic expression of human decay-accelerating factor on the inhibition of pig organs. In Xenotransplantation, edition 2, Berlin: Springer-Verlag; 1997 (in press).
39. Bach FH, Robson SC, Winkler H, Ferran C, Stuhlmeier KM, Wrighton CJ, Hancock WW: Barriers to xenotransplantation. Nature Med 1995, 1:869-873. This paper is a brief and comprehensive review on the role played by endothelial cell activation and the coagulation mechanisms in the rejection of a xenograft in discordant xenocombinations. The possible targets for genetic engineering of endothelial cells are also reviewed.
40. Saadi S, Platt JL: Transient perturbation of endothelial integrity induced by natural antibodies and complement. J Exp Med 1995, 181:21-31. This paper reports that exposure of porcine endothelial cells to human XNAs and complement leads to alterations in the cell shape and in the cytoskeleton, which disrupt the monolayer integrity and lead to the formation of intercellular gaps.
41. Saadi S, Holzknecht RA, Patte CP, Stern DM, Platt JL: Complement-mediated regulation of tissue factor activity in endothelium. J Exp Med 1995, 182:1807-1814. This paper demonstrates that cell-surface expression of tissue factor activity requires the activation of complement and the assembly of the membrane attack complex. Expression of tissue factor was a secondary response which required, as an intermediate step, the release of IL-1a, an early product of the endothelial cell response to complement activation.
42. Yamada K, Sachs DH, Dersimonian H: Human anti-porcine xenogeneic T cell response: evidence for allelic specificity of mixed leukocyte reaction and for both direct and Indirect pathways of recognition. J Immunol 1995, 155:5249-5256. This paper describes, in detail, the role of the human anti-porcine T cell response in mixed leucocyte reaction and compares it with the allogeneic response.
43. Vallée I, Watier H, Thibault G, Salmon H, Gruel Y, Lebranchu Y, Bardos P: Evidence of non-involvement of swine MHC class II in the in-vitro proliferative response of human lymphocytes to porcine endothelial cells. Transplantation 1995, 59:897-901.
44. Chan DV, Auchincloss H: Human anti-pig cell-mediated cytotoxicity in vitro involves non-T as well as T cell components. Xenotransplantation 1996, 3:158-165.
45. Dorling A, Binns R, Lechler RI: Cellular xenoresponses: although vigorous, direct human T cell anti-pig primary xenoresponses are significantly weaker than equivalent alloresponses. Xenotransplantation 1996, 3:149-157.
46. Seebach JD, Yamada K, McMorrow IM, Sachs DH, Dersimonian H: Xenogeneic human anti-pig cytotoxicity mediated by activated natural killer cells. Xenotransplantation 1996, 3:188-197.
47. Goodman DJ, Von Albertini M, Willson A, Millan MT, Bach FH: Direct activation of porcine endothelial cells by human natural killer cells. Transplantation 1996, 61:763-771.
48. Malyguine AM, Saadi S, Platt JL, Dawson JR: Human natural killer cells Induce morphologic changes in porcine endothelial cell monolayers. Transplantation 1996, 61:161-164.